TURKU, FI / ACCESS Newswire / April 17, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel imm ...

Faron Pharmaceuticals Ltd | Company announcement | April 17, 2025 at 15:15:00 EEST ...

A PTSD diagnosis also includes some different non-fear-based symptoms that aren't part of the acute stress disorder diagnosis ...

The study shows that, compared with lean animals, obesity significantly impacts echocardiographic findings, infarct size, circulating biomarkers, mitochondrial respiratory capacity and mortality ...

In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS ... MN-166 (ibudilast), is currently in Phase 3 for amyotrophic ...

Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory ...

We describe the clinical, radiological and histological findings of patients with COVID‑19-associated acute respiratory distress syndrome who later developed ... for the therapeutic modalities in the ...

The role of lung-protective strategies in patients without ARDS is less conclusive. 10 In this issue of the Jornal Brasileiro de Pneumologia, Bastos-Netto et al. 11 provide important data regarding ...

Objective To investigate whether gut microbiome composition is linked to post-acute COVID-19 syndrome (PACS), defined as at least one persistent symptom 4 weeks after clearance of the SARS-CoV-2 virus ...